Navigation Links
MitoAction Develops On-Line Resource for Mitochondrial Disease Care Providers
Date:7/23/2008

Online Clinicians Guide to Mitochondrial Disease Now Available, sponsored by Edison Pharma

Boston (PRWEB) July 23, 2008 -- MitoAction.org announces today the completion of the Clinicians Symptom Guide to MITO Management, a comprehensive online resource designed to assist primary care providers in the care and symptom management of patients affected by mitochondrial disease. The Clinicians Symptom Guide to MITO Management fills a gap in healthcare libraries which to date have offered no practical overview for patient management. MitoAction fulfills their mission to support, educate and advocate for the mitochondrial disease patient community through development of the Clinicians Symptom Guide to MITO Management.

Mitochondrial disease is an energy metabolism disorder found in approximately one in 4,000 individuals in the U.S. The disease affects children as well as adults, and commonly manifests with neuromuscular symptoms such as stroke, muscle pain, extreme fatigue, and organ failure. There are no FDA approved drugs for mitochondrial disease. Symptoms vary widely from patient to patient; in many cases, the disease is inherited.

Written in collaboration with Margaret Klehm, CPNP and Mark Korson MD of the Floating Hospital for Children at Tufts Medical Center, the Clinicians Symptom Guide to MITO Management is the only resource of its kind. The Clinicians Symptom Guide to MITO Management is now freely available to the public online at http://www.mitoaction.org/. In light of the recent attention to the autism-mitochondrial disease connection, the need for this practical and comprehensive resource is apparent. This information needs to be accessed by the public and medical providers in order to improve quality of life and care for the person suffering from 'Mito,' says Cristy Balcells, Executive Director of MitoAction.

Dr. Korson is a leading clinician in the field of mitochondrial medicine, and has treated over 1,000 mitochondrial disease patients. This community of patients is terribly under-recognized and underserved. There are simply not enough clinicians aware of Mito, or who will play an active role in the care of these patients. As a result, it is too often the patient or the family member who becomes the de facto primary care provider.

MitoAction anticipates that the Clinicians Symptom Guide to MITO Management will improve baseline care and understanding of the complexities of mitochondrial disease, as well as educate pediatricians, primary care physicians, and home health nurses about managing the disease.

Edison Pharma (http://edisonpharma.com) is the dedicated sponsor for the project. We are honored to support the development of this important resource for clinicians and care-providers, stated Guy Miller, MD, PhD, CEO of Edison. This is a wonderful initiative that will go a long way to standardizing care for patients with mitochondrial disorders. MitoAction is grateful for Edisons support for this project to improve patient care for those affected by mitochondrial disease.

Further questions may be directed to Cristy Balcells, RN MSN Executive Director at 423-914-8322 or director @ mitoaction.org

SOURCE MitoAction

###

Read the full story at http://www.prweb.com/releases/2008/07/prweb1134624.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related medicine news :

1. HighPoint Solutions Develops Novel Incentive Compensation Plan for New Benign Prostatic Hyperplasia (BPH) Product
2. URAC Develops New Case Management Patient Satisfaction Tool, Invites Public Input On Voluntary Survey Instrument
3. China Sky One Medical, Inc. Successfully Develops Semi-Quantitative Automatic Inspection Device for Diagnostic Kits
4. SellingLTC.com Develops simplifyingLTC
5. Medical Records Institute (MRI) Develops Initiative for EMRs Supporting Medicolegal Requirements
6. Psychologist develops post-operative care for heart patients in Bermuda
7. Omron Healthcare Develops Solar-Powered Digital Blood Pressure Monitors
8. MIT develops thin-film micro pharmacy
9. Capsulated Systems, Inc. Develops Long Term Local Anesthetic
10. OHSU Cancer Institute researcher develops test for targeted therapy in acute myeloid leukemia
11. Silverchair Learning Systems Updates and Develops New Courses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... DC (PRWEB) , ... March 30, 2017 , ... ... and organizations submitted a letter to President Trump expressing their support for an ... medical doctors, two Ph.D. scientists and one medical journalist, will hold a press ...
(Date:3/29/2017)... ... March 29, 2017 , ... In the United States alone, up ... year develop other types of metastatic brain tumors(3). Though most meningiomas are benign, metastatic ... focus on finding more effective treatment options, the San Diego Gamma Knife Center ...
(Date:3/29/2017)... ... 2017 , ... Grass pollen is the main cause of hay fever in the United States, ... grass pollen runs from May to July each year; with the worst time for sufferers ... allergen barrier balms ( http://www.haymax.us ) provide an effective defense against grass pollen; they are ...
(Date:3/29/2017)... FL (PRWEB) , ... March 30, 2017 , ... Sublime ... the "Spice of Life" or "Wonder Spice", it has been used for thousands of ... in the East," says Heshelow, author of " Turmeric: How to Use it For ...
(Date:3/29/2017)... ... March 29, 2017 , ... AngioGenesis Labs ... store in Mississippi. AngioGenesis Labs, makers of HeartBoost, BrainBest and BeautyBest, achieved these ... Ingredients in HeartBoost, an over the counter heart healthy drink, can reduce Arterial ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... -- Wound care devices and products are used to ... industry mainly consists of establishments engaged in manufacturing wound ... caused by mechanical, chemical, thermal, and radiogenic trauma; and ... skin related diseases, immunological diseases, and other chronic diseases. ... largest region in the wound care devices market in ...
(Date:3/29/2017)... , March 29, 2017 Global intravenous (IV) iron ... billion by 2021, growing at a CAGR of 5%. ... by a doctor to treat anemia or other iron deficiencies. ... in the body. However, in some cases, oral administrations are ... and intravenous (IV) iron therapy comes into the picture. ...
(Date:3/29/2017)... N.J. , March 29, 2017  Novartis ... Administration (FDA) has accepted the company,s Biologics License ... CTL019 (tisagenlecleucel-T), an investigational chimeric antigen receptor T ... pediatric and young adult patients with B-cell acute ... submission by Novartis for a CAR-T. The priority ...
Breaking Medicine Technology: